Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is at the forefront of the discovery and clinical development of pioneering medicines targeting severe, rare diseases. Leveraging unique insights into physiocrine biology, a newly identified group of physiological modulators, aTyr aims to deliver breakthrough treatments to patients in need.
The company's flagship candidate, resolaris™, is a first-in-class intravenous protein therapeutic designed to address rare myopathies with an immune component. Resolaris™ is undergoing a series of Phase 1b/2 clinical trials, including trials for adult patients with facioscapulohumeral muscular dystrophy (FSHD), limb girdle muscular dystrophy (LGMD) 2B or FSHD, and patients with an early onset form of FSHD.
aTyr Pharma holds a substantial intellectual property portfolio, featuring 70 issued or allowed patents and over 240 pending patent applications, all of which are solely owned or exclusively licensed by the company. This robust IP estate underpins their strategic focus on severe, rare diseases characterized by immune dysregulation.
One of the company’s notable recent achievements includes the development of efzofitimod, a first-in-class NRP2-targeting immunomodulator. Preclinical models have demonstrated that efzofitimod has significant immune regulatory functions, improving disease outcomes and mitigating fibrosis, particularly in rheumatoid arthritis and associated lung fibrosis.
In addition to its innovative drug pipeline, aTyr Pharma has bolstered its leadership and expertise by enlisting Dr. Frederick to guide corporate affairs and commercial strategies for efzofitimod in interstitial lung disease (ILD).
For the most current updates and detailed information, investors can contact Ashlee Dunston, Director of Investor Relations and Public Affairs, at adunston@atyrpharma.com.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced on March 25, 2022, that its Compensation Committee granted stock options to ten employees, totaling 58,400 shares. The exercise price for these options is set at $5.24, aligning with the stock's closing price on March 21, 2022. These awards are designed to incentivize new employees as per Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% vesting after one year and the remainder monthly. aTyr is focused on developing innovative medicines targeting tRNA synthetases and is advancing its clinical-stage candidate, efzofitimod, for fibrotic lung disease.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced positive developments regarding efzofitimod (ATYR1923) for pulmonary sarcoidosis following a favorable End-of-Phase 2 meeting with the FDA. The company plans to initiate a registrational trial in Q3 2022.
As of December 31, 2021, aTyr's cash and investments totaled $107.9 million, supporting its R&D efforts. The FDA granted orphan drug designation for efzofitimod, offering potential market exclusivity and financial benefits. The company also announced a partnership with FUJIFILM Diosynth Biotechnologies for efzofitimod's manufacturing.
aTyr Pharma has announced a positive outcome from its Type B End-of-Phase 2 meeting with the FDA regarding its lead candidate, efzofitimod (ATYR1923), aimed at treating pulmonary sarcoidosis. The company plans to initiate a registrational study in Q3 2022, incorporating FDA feedback, including the importance of steroid-sparing effects. This follows successful data from early clinical trials demonstrating efzofitimod's safety and potential efficacy. The ongoing development reflects a significant milestone for aTyr in its commitment to providing new therapeutic options for patients.
aTyr Pharma (Nasdaq: LIFE) announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The poster, titled 'ATYR2810, a fully humanized monoclonal antibody targeting the VEGF-NRP2 pathway,' will focus on its potential to sensitize aggressive and chemoresistant TNBC subtypes to chemotherapy. ATYR2810 is in IND-enabling studies aimed at targeting NRP2, associated with poor outcomes in various cancers, suggesting significant therapeutic potential.
aTyr Pharma (Nasdaq: LIFE) announced it will release its Q4 and full year 2021 financial results on March 14, 2022, after the market close. The management will host a conference call and webcast at 5:00 PM EDT to discuss the results and provide a corporate update. aTyr focuses on discovering and developing innovative medicines from novel biological pathways, particularly through its product candidate efzofitimod, targeting inflammatory lung diseases.
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, a biotherapeutics company focused on innovative medicines, will have its President and CEO, Sanjay S. Shukla, present at two investor conferences in March 2022. The first is the 34th Annual ROTH Conference from March 13-15, featuring a pre-recorded presentation. The second, the Oppenheimer 32nd Annual Healthcare Conference, is on March 16 at 4:40 PM EDT. One-on-one investor meetings will also be held. Replays of the presentations will be available on their website.
aTyr Pharma (Nasdaq: LIFE) announced its participation in the NIH Rare Disease Day virtual conference on February 28, 2022, at 2:55pm EST. Sanjay S. Shukla, M.D., CEO, will join a panel discussing strategies for clinical trial recruitment, emphasizing lessons learned from the Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis during the pandemic. The event features industry leaders advocating for rare diseases awareness. aTyr is currently developing efzofitimod for severe inflammatory lung diseases, with a registrational trial expected to start this year.
aTyr Pharma (Nasdaq: LIFE) announced that its President and CEO, Sanjay S. Shukla, will present a corporate overview at the BIO CEO & Investor Conference from February 14 to 17, 2022, at the Marriott Marquis, New York.
The presentation is scheduled for February 15, 2022, at 1:15 p.m. EST. Additionally, aTyr management will engage in both in-person and virtual one-on-one meetings during the conference. More information about aTyr's innovative biotherapeutics focusing on tRNA synthetases can be found at www.atyrpharma.com.
aTyr Pharma has announced the nonproprietary name efzofitimod for its drug ATYR1923, which is under clinical development for pulmonary sarcoidosis. The company aims to initiate a registrational trial in 2022. Efzofitimod, an immunomodulator targeting neuropilin-2, is engineered from a splice variant of histidyl-tRNA synthetase and is viewed as a potential treatment for severe inflammatory lung diseases. Initial Phase 1b/2a clinical trials showed promising safety and efficacy, including improvements in lung function and reduced steroid use.
aTyr Pharma (Nasdaq: LIFE) announced that the FDA granted orphan drug designation for its candidate ATYR1923, aimed at treating pulmonary sarcoidosis, a chronic inflammatory disease affecting nearly 200,000 patients in the U.S. This milestone is significant as ATYR1923 may offer a transformative alternative to current treatments that are often limited and come with severe side effects. The company expects to begin a registrational trial this year after establishing clinical proof-of-concept in a recent Phase 1b/2a study.
FAQ
What is the current stock price of aTyr Pharma (LIFE)?
What is the market cap of aTyr Pharma (LIFE)?
What does aTyr Pharma, Inc. specialize in?
What is aTyr Pharma's leading drug candidate?
In which clinical trial phases is resolaris™ currently?
What is the significance of physiocrine biology for aTyr Pharma?
How strong is aTyr Pharma's intellectual property portfolio?
What is efzofitimod?
Who can investors contact for more information?
What recent strategic addition did aTyr Pharma make?
When will aTyr Pharma's ticker symbol change take effect?
What is the focus of aTyr Pharma's key programs?
